Literature DB >> 19960013

Preparation, characterization, in vivo and in vitro studies of arsenic trioxide Mg-Fe ferrite magnetic nanoparticles.

Guo-fu Yang1, Xiang-hui Li, Zhe Zhao, Wen-bo Wang.   

Abstract

AIM: MgFe(2)O(4) magnetic nanoparticle composed of As(2)O(3) (As(2)O(3)-MNPs) were prepared and their in vitro and in vivo characteristics were studied.
METHODS: The solvent-displacement method was applied for preparation of the nanoparticle using Poly-D,L-lactic-co-glycolic acid(PLGA). The characteristics studies of the products included magnetic response, morphology (transmission electron microscopy and scanning electron microscopy), entrapment efficiency, drug loading, particle sizes, zeta potential, in vitro drug release and tissue magnetic targeting. Nanoparticle cytotoxicity to Saos-2 cells was investigated using the MTT assay. To guide the external magnetic field in the liver, the concentration of As(2)O(3) in the liver and kidney was measured using an atomic fluorescence spectrometer after injecting As(2)O(3)-MNPs into the caudal veins of mice.
RESULTS: The As(2)O(3)-MNPs were approximately spherical. The average diameter, drug loading, entrapment efficiency and zeta potential of As(2)O(3)-MNPs were 109.9 nm, 10.08%, 82.16%, and -14.33 mV, respectively. The specific saturation magnetism was 8.65 emu/g. In vivo, the concentration of As(2)O(3) in the liver was significantly higher than that in the non-magnetic group. While the concentration of As(2)O(3) in the kidney was lower than that in the non-magnetic group. The C(max) in liver tissue in the magnetic group was 30.65 microg/g, which was 4.17 times the drug concentration in the same group in kidney tissue (7.35 microg/g) and 2.88 times the concentration of drug (10.66 microg/g) in the liver tissue of the non-magnetic group.
CONCLUSION: The PLGA polymer-loaded magnetic nanoparticle composed of arsenic trioxide can be magnetically targeted well and applied in biomedicine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19960013      PMCID: PMC4007504          DOI: 10.1038/aps.2009.158

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  17 in total

1.  Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis.

Authors:  Jin Zhou; Ran Meng; Xinhua Sui; Lu Meng; Jianping Jia; Baofeng Yang
Journal:  Haematologica       Date:  2005-09       Impact factor: 9.941

2.  Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy.

Authors:  Robert J Griffin; Brent W Williams; Heon Joo Park; Chang W Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

3.  Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown.

Authors:  Y S Lew; S L Brown; R J Griffin; C W Song; J H Kim
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

4.  Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis.

Authors:  Ernesto Montoro; Dihadenys Lemus; Miguel Echemendia; Anandi Martin; Françoise Portaels; Juan Carlos Palomino
Journal:  J Antimicrob Chemother       Date:  2005-02-24       Impact factor: 5.790

Review 5.  Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.

Authors:  Wen-Chien Chou; Chi V Dang
Journal:  Curr Opin Hematol       Date:  2005-01       Impact factor: 3.284

6.  Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.

Authors:  A Ghavamzadeh; K Alimoghaddam; S H Ghaffari; S Rostami; M Jahani; R Hosseini; A Mossavi; E Baybordi; A Khodabadeh; M Iravani; B Bahar; Y Mortazavi; M Totonchi; N Aghdami
Journal:  Ann Oncol       Date:  2005-10-14       Impact factor: 32.976

Review 7.  Mechanisms of action of arsenic trioxide.

Authors:  Wilson H Miller; Hyman M Schipper; Janet S Lee; Jack Singer; Samuel Waxman
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

Review 8.  How acute promyelocytic leukaemia revived arsenic.

Authors:  Jun Zhu; Zhu Chen; Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

9.  A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew M Rauth; Hui Yi Xue; Karlo Babakhanian; Xiao Yu Wu
Journal:  J Pharmacol Exp Ther       Date:  2006-03-17       Impact factor: 4.030

10.  Stability of hydrophilic magnetic nanoparticles under biologically relevant conditions.

Authors:  Z P Chen; Y Zhang; K Xu; R Z Xu; J W Liu; N Gu
Journal:  J Nanosci Nanotechnol       Date:  2008-12
View more
  2 in total

1.  Cytotoxicity of nickel zinc ferrite nanoparticles on cancer cells of epithelial origin.

Authors:  Mothanna Sadiq Al-Qubaisi; Abdullah Rasedee; Moayad Husein Flaifel; Sahrim H J Ahmad; Samer Hussein-Al-Ali; Mohd Zobir Hussein; Eltayeb E M Eid; Zulkarnain Zainal; Mohd Saeed; Muna Ilowefah; Sharida Fakurazi; Norhaszalina Mohd Isa; Mohamed Ezzat El Zowalaty
Journal:  Int J Nanomedicine       Date:  2013-07-15

2.  Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.

Authors:  Degang Kong; Tao Jiang; Jian Liu; Xinyi Jiang; Bei Liu; Cheng Lou; Baobing Zhao; Steven L Carroll; Gong Feng
Journal:  Drug Deliv       Date:  2020-11-26       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.